BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19543385)

  • 1. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.
    Romanova J; Krenn BM; Wolschek M; Ferko B; Romanovskaja-Romanko E; Morokutti A; Shurygina AP; Nakowitsch S; Ruthsatz T; Kiefmann B; König U; Bergmann M; Sachet M; Balasingam S; Mann A; Oxford J; Slais M; Kiselev O; Muster T; Egorov A
    PLoS One; 2009 Jun; 4(6):e5984. PubMed ID: 19543385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
    Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C
    Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    Suguitan AL; McAuliffe J; Mills KL; Jin H; Duke G; Lu B; Luke CJ; Murphy B; Swayne DE; Kemble G; Subbarao K
    PLoS Med; 2006 Sep; 3(9):e360. PubMed ID: 16968127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.
    Krenn BM; Egorov A; Romanovskaya-Romanko E; Wolschek M; Nakowitsch S; Ruthsatz T; Kiefmann B; Morokutti A; Humer J; Geiler J; Cinatl J; Michaelis M; Wressnigg N; Sturlan S; Ferko B; Batishchev OV; Indenbom AV; Zhu R; Kastner M; Hinterdorfer P; Kiselev O; Muster T; Romanova J
    PLoS One; 2011 Apr; 6(4):e18577. PubMed ID: 21490925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].
    Romanovskaia-Roman'ko EA; Ferko B; Vyshemirskiĭ OI; Romanova IuR; Krenn B; Muster T; Grudinin MP; Lapin BA; Egorov AIu; Kiselev OI
    Vopr Virusol; 2011; 56(6):19-22. PubMed ID: 22359944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
    Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
    Alexander J; Ward S; Mendy J; Manayani DJ; Farness P; Avanzini JB; Guenther B; Garduno F; Jow L; Snarsky V; Ishioka G; Dong X; Vang L; Newman MJ; Mayall T
    PLoS One; 2012; 7(2):e31177. PubMed ID: 22363572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
    Smith D; Streatfield SJ; Acosta H; Ganesan S; Fattom A
    Vaccine; 2019 Sep; 37(42):6162-6170. PubMed ID: 31495593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
    Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
    J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a New Viral Vaccine Vector in Mice and Rhesus Macaques: J Paramyxovirus Expressing Hemagglutinin of Influenza A Virus H5N1.
    Abraham M; Beavis AC; Xiao P; Villinger FJ; Li Z; Jones CA; Tompkins SM; He B
    J Virol; 2021 Oct; 95(22):e0132121. PubMed ID: 34469242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
    Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
    Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two dose immunization with an inactivated reassortant H5N2 virus protects chickens against lethal challenge with homologous 2.3.2.1 clade and heterologous 2.2 clade highly pathogenic avian influenza H5N1 viruses.
    Bhat S; Sood R; Shukla S; Khandia R; Pateriya AK; Kumar N; Singh VK; Kalaiyarasu S; Kumar M; Bhatia S
    Vet Microbiol; 2018 Apr; 217():149-157. PubMed ID: 29615248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility.
    Shelton H; Roberts KL; Molesti E; Temperton N; Barclay WS
    J Gen Virol; 2013 Jun; 94(Pt 6):1220-1229. PubMed ID: 23486663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.
    Matsuoka Y; Suguitan A; Orandle M; Paskel M; Boonnak K; Gardner DJ; Feldmann F; Feldmann H; Marino M; Jin H; Kemble G; Subbarao K
    J Virol; 2014 Jul; 88(14):8139-52. PubMed ID: 24807726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.
    Steel J; Lowen AC; Pena L; Angel M; Solórzano A; Albrecht R; Perez DR; García-Sastre A; Palese P
    J Virol; 2009 Feb; 83(4):1742-53. PubMed ID: 19073731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
    Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.